Send Inquiry

Request To Call Back

Keytruda 100 mg Injection

Name: Keytruda 100 mg Injection
Brand: SIDMEX INOVIA PRIVATE LIMITED
Price: 175207.0 INR
Availability: InStock

Price 175207.0 INR/ Piece

Get a Price/Quote

MOQ : 2 Pieces

Keytruda 100 mg Injection Specification

Life Span
Refer to expiry date on packaging

Dosage Form
Injectable solution

Packaging Type
Sealed glass vial

Brand Name
Keytruda

Pacakaging (Quantity Per Box)
1 vial per box

Origin of Medicine
INDIA

Indication
Advanced cancers including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and others

Salt Composition
Pembrolizumab

Drug Type
Biological, monoclonal antibody

Ingredients
Pembrolizumab (100 mg) in 4 ml solution

Physical Form
Liquid

Function
Immune checkpoint inhibitor for cancer treatment

Recommended For
DOCTOR

Dosage
Administered as an intravenous infusion over 30 minutes

Dosage Guidelines
To be administered only under the supervision of a qualified healthcare professional; refer to physician guidance

Suitable For
Cancer patients as prescribed by a healthcare professional

Quantity
2 Pieces

Storage Instructions
Store in a refrigerator (2C - 8C), do not freeze

Prescription Required
Yes

International Brand Name
Keytruda

Side Effects
Fatigue, pruritus, rash, diarrhea, nausea, and infusion-related reactions

Contraindications
Hypersensitivity to pembrolizumab or excipients

Dilution Instructions
Dilute prior to administration according to the package insert

Reconstitution Required
No, ready to use

Therapeutic Class
Anti-cancer immunotherapy

ATC Code
L01XC18

Strength
100 mg/4 ml

Shelf Life After Opening
Use immediately after opening or as per instructions

Administration Route
Intravenous

Keytruda 100 mg Injection Trade Information

Minimum Order Quantity
2 Pieces

Supply Ability
1000 Pieces Per Month

Delivery Time
1 Week

About Keytruda 100 mg Injection

Keytruda 100 mg injection is an innovative immunotherapy designed to combat various cancers, including melanoma, non-small cell lung cancer, head and neck cancers, and cervical cancer. This medication works by harnessing the bodys immune system, specifically targeting the PD-1 pathway to help the immune system recognize and destroy cancer cells more effectively. Patients receiving Keytruda may experience side effects such as fatigue, rash, or flu-like symptoms, and it is crucial to inform healthcare providers about any existing medical conditions or medications to avoid potential interactions. Due to its immunomodulatory effects, monitoring for autoimmune reactions is essential throughout treatment. Keytruda has transformed the approach to cancer care, offering hope to many who have limited treatment options. It is administered via injection, typically every three weeks, making it a convenient choice for patients. As always, discussing treatment plans with a healthcare professional ensures the best approach tailored to individual needs. This cutting-edge therapy exemplifies the advancements in oncology, emphasizing the importance of personalized medicine.

Advanced Immune Checkpoint Inhibitor

Keytruda 100 mg Injection utilizes pembrolizumab, a monoclonal antibody designed to target and block PD-1 proteins. This mechanism helps reinvigorate the immune system, allowing it to recognize and attack cancer cells more effectively. The treatment is suitable for various late-stage cancers, including those that may not have responded to previous therapies.

Ready-to-Use Injectable Solution

This product is supplied as a 4 ml liquid in a sealed glass vial, containing 100 mg pembrolizumab. No reconstitution is needed, simplifying preparation for clinical administration. Dilution instructions must be followed as specified in the package insert to ensure safe and effective use.

Strict Handling and Storage Instructions

To maintain drug stability, Keytruda should be stored refrigerated (2C - 8C) and must not be frozen. After opening, the solution must be used immediately or according to the manufacturer's guidelines. Always refer to the expiry date indicated on the packaging for safety.

FAQ's of Keytruda 100 mg Injection:

Q: How is Keytruda 100 mg Injection administered to patients?

A: Keytruda is administered as an intravenous infusion over 30 minutes. It should only be given by a qualified healthcare professional in a clinical setting, following physician instructions for dosage and dilution as per the package insert.

Q: What cancers is Keytruda commonly used to treat?

A: Keytruda is indicated for advanced cancers such as melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and certain other malignancies where immune checkpoint inhibition may provide benefit.

Q: What are the main benefits of using Keytruda for cancer treatment?

A: Keytruda helps the body's immune system better recognize and destroy cancer cells by inhibiting the PD-1 pathway, potentially improving outcomes in patients with specific advanced cancers compared to traditional treatments.

Q: What side effects may occur with Keytruda 100 mg Injection?

A: Common side effects include fatigue, pruritus, rash, diarrhea, nausea, and infusion-related reactions. It is important to report any adverse effects to your healthcare provider for proper management.

Q: How should Keytruda be stored prior to use?

A: Keytruda should be kept refrigerated between 2C and 8C in its sealed glass vial and should never be frozen. Always check the expiry date and use immediately after opening or as per the provided instructions.

Q: Is any preparation required before administering Keytruda?

A: Keytruda is supplied as a ready-to-use liquid solution; reconstitution is not needed. However, it must be diluted as directed in the package insert before intravenous administration.

Q: Who should avoid receiving Keytruda 100 mg Injection?

A: Patients with known hypersensitivity to pembrolizumab or any excipients in the formulation should not receive this medication. Always consult a healthcare professional to determine individual suitability for treatment.

Tell us about your requirement